This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Varian Receives Regulatory Clearance In India For Use Of High Intensity Mode On TrueBeam Medical Linear Accelerators

Stocks in this article: VAR

KOLKATA, India, Nov. 29, 2012 /PRNewswire/ -- Varian Medical Systems (NYSE: VAR) has received regulatory clearance from the Indian Atomic Energy Regulatory Board for the use of its unique TrueBeam™ High Intensity Mode for advanced radiosurgical treatments.  The company's market-leading range of radiotherapy and radiosurgery equipment and software, including the TrueBeam medical linear accelerator, are on display in Kolkata this week at AROICON 2012, the country's primary radiation oncology exhibition.

Dr. Vivek Bansal, director of radiation oncology at HCG Cancer Hospital in Ahmedabad -- the first hospital in India to commence treating patients using the TrueBeam high intensity mode – said, "We have used this modality for prostate, head & neck and lung cancer patients, enabling quicker dose delivery and therefore shorter treatments. Higher dose rates appear to offer considerable benefits in organ motion management -- for example, larger dose fractions have been delivered in a single breath-hold at our center."

"We feel high intensity modes may become necessary for most stereotactic ablative body radiotherapy and stereotactic radiosurgery treatments in the future," said Dr. Bansal. "Our experience is showing that high intensity mode treatments offer particular advantages when treating the smaller field sizes normally seen in such treatments."

Varian's TrueBeam was designed to treat tumors with unprecedented speed and accuracy. It features a multitude of technical innovations that dynamically synchronize imaging, patient positioning, motion management, and treatment delivery. With its High Intensity Mode, TrueBeam machines can deliver very high doses quickly and precisely, more than twice as fast as earlier generations of technology.  The TrueBeam™ STx is a high-end model optimized for radiosurgical applications, where very large doses are delivered in a single treatment or only a few sessions.

Such advanced treatments will be highlighted at an Emerging Technologies Symposium that Varian is hosting at the ITC Sonar Hotel on the first day of the AROICON exhibition, with presentations on high dose single-fraction IGRT treatments with TrueBeam STx, RapidArc® for head & neck treatments, and advanced radiobiology and stereotaxy treatments, from presenters including Prof. Carlo Greco of the University of Pisa in Italy, Dr. Luca Cozzi of the Oncology Institute of Southern Switzerland in Bellinzona, and Dr. Rimpa Basu Achari of Tata Medical Center in Kolkata.

"The high dose rates that only Varian can offer on its medical linear accelerators are vital for the sort of stereotactic ablative radiotherapy treatments that are used increasingly for primary liver, liver metastasis and lung cancer treatments," said Rolf Staehelin, international head of marketing operations for Varian's Oncology Systems group. "Regulatory approval means cancer patients in India can now benefit from such advanced treatments."

"With the largest installed base of linear accelerators in India and market-leading position in new systems, Varian continues to equip the country's cancer hospitals with technologies that make advanced radiotherapy techniques fast and easy to deliver," added Ashok Kakkar, managing director of Varian India. "We have also established a dedicated education center in Mumbai because helping to train the nation's radiotherapists and physicists in the safe and effective use of Varian's products is crucial for the future care of India's growing cancer population."

Cancer in India

India has a population of over a billion people and there are an estimated one million new cases of cancer diagnosed in the country each year. The most common forms of cancer for females in India are cervical and breast, while lung and stomach are the leading cancers for males.

Editorial contact: Neil Madle, Varian Medical Systems, +44 7786 526068

About Varian Medical Systems

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes, digital detectors, and image processing workstations for X-ray imaging in medical, scientific, and industrial applications and also supplies high-energy X-ray devices for cargo screening and non-destructive testing applications.  Varian Medical Systems employs approximately 6,100 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit http://www.varian.com or follow us on https://twitter.com/VarianMedSys

SOURCE Varian Medical Systems

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,359.38 +163.96 0.95%
S&P 500 0.00 -2.75 -0.14%
NASDAQ 4,627.7180 +61.58 1.35%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs